RESEARKA

This discrepancy between null pharmacokinetic findings in healthy volunteers and positive clinical outcomes in patients with cardiovascular disease reflects a broader challenge in translating early-phase data to clinical practice. The observational cohort design of the pharmacokinetic study limits direct comparison with the randomized controlled trial data, yet both contribute essential pieces to the overall efficacy-safety profile. Future research integrating long-term pharmacokinetic data with hard clinical endpoints, such as mortality and cardiovascular event reduction, will be necessary to fully characterize the dose-response relationship relevant to longevity outcomes. Currently, the evidence supports robust LDL-C lowering but leaves open questions about optimal dosing for anti-aging benefits.

Citation Support

• source_1 Ma 2025
• source_2 Schwartz 2021
• source_3 Lehrke 2024
• source_4 Imran 2023
• source_5 Faraidy 2023